AstraZeneca says its vaccine needs additional study

AstraZeneca says its vaccine needs additional study

The other two main candidates of the coronavirus vaccine, i-e, Pfizer, and Moderna, have shown 90 percent effectiveness. "Even the stability data supporting the vaccine expiration and optimum temperature is also important in order to ensure vaccine quality, if used within the recommended temperature range", he said.

Gillies O'Bryan-Tear, from the UK Faculty of Pharmaceutical Medicine, said "the eventual efficacy rate may change" but "the validity of the low dose/high dose group results are unlikely to be questioned".

Moderna's experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial.

The FAA said in a statement Friday that it was supporting the "first mass air shipment of a vaccine", and that it is working with airlines to safely transport Covid-19 vaccines.

The Oxford vaccine has around 100 million pre-orders, including U.K's government orders from what is known until now.

"Even if they (the regulators) made a decision to ignore the results of the low dose/high dose group, the study of the high dose/high dose patients will still be strongly significant, but I think that it unlikely", he added. He said these are fantastic results but still need necessary safety checks to roll out for the human population's major parts.

Astrogeneca vaccine needs "more than a press release" to evaluate test results. Producing such a vaccine in a span of 10 months is something really remarkable.

But Pauline Londeix, co-founder of French drug transparency group OT-Med, said apparent confusion over the trial results was "very problematic for public confidence in vaccines".

The Oxford and AstraZeneca jab could be rolled out within weeks if approved by the MHRA, with the United Kingdom having close to 100 million doses on order. It's expected that frontline workers, including hospital staff, will be among the first to receive doses after government approvals.

AstraZeneca expects 4 million doses to be available in Britain by the end of December.

AstraZeneca/Oxford has also promised to provide its vaccine to the developing world on a non-profit basis. The Oxford vaccine injects the recipients with a blueprint of the coronavirus, which resembles the spike protein that has been classified as risky to humans previously.

The airline reportedly had to request an official exception to be able to carry additional dry ice (frozen carbon dioxide) to keep the Pfizer vaccine cold during transport.

Related Articles